New subcutaneous formulation of natalizumab (Tysabri) approved in UK for the treatment of multiple sclerosis

The approval, which follows EU approval in March, is based on data from the DELIVER (Phase I) and REFINE (Phase II) studies, in which the subcutaneous formulation demonstrated comparability to IV administration in efficacy, pharmacokinetic and pharmacodynamics profiles.

Source:

PharmaTimes